Akademik Veri Yönetim Sistemi
Cocuk Enfeksiyon Dergisi, cilt.8, sa.4, ss.178-186, 2014 (SCI-Expanded)
© 2014 by Pediatric Infectious Diseases Society.Invasive meningococcal disease is a serious and global life-threatening disease. It affects more than 500.000 people worldwide annually, with 50.000 deaths and 50.000-100.000 severe sequelae, despite treatment. Six serogroups (A, B, C, W135, X, and Y) account for the majority of cases of meningococcal disease worldwide. Meningococcal polysaccharide vaccines were introduced several decades ago and have led to the decline in the burden of disease. However, these vaccines have several limitations, including poor immunogenicity in infants and toddlers, short-lived protection, lack of immunologic memory and herd immunity, and negligible impact on nasopharyngeal carriage. The conjugation of polysaccharide vaccines has the potential to overcome these drawbacks. Herein, we reviewed the new information about the quadrivalent conjugated meningococcal vaccines and meningococcal serogroup B vaccines.